Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Beijing’s New Fast-track Review For Innovative Medicines Might Be Open Only To Made-in-China Drugs

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's fast-track review process for certain classes of new drugs, unveiled earlier this month, marks an advance in the country's budding support for innovative medicines, but also might be open only to domestically made products, according to Chinese and American lawyers

You may also be interested in...



China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan

China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan

Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

Table

View full table

Related Content

Scrip
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC069902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By